Trial Profile

Multicenter Study of Options for Second-Line Effective Combination Therapy (SELECT)

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 18 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Abacavir; Emtricitabine/tenofovir disoproxil fumarate; Lamivudine; Lamivudine/abacavir; Lamivudine/zidovudine; Lamivudine/zidovudine/abacavir; Lopinavir/ritonavir; Nucleoside reverse transcriptase inhibitors; Raltegravir; Zidovudine
Indications HIV-1 infections
Focus Therapeutic Use
Acronyms SELECT

Most Recent Events

05 Aug 2021 Biomarkers information updated
06 Sep 2013 Status changed from recruiting to active, no longer recruiting as reported by Clinical Trials Registry - India record.
25 Jul 2013 Planned end date changed from 1 Apr 2015 to 1 Nov 2015 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com